Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy

American Journal of Transplantation

Volumn 13, Issue 12, 2013, Pages 3244-3252

  Ricciardelli, I ^a,b   Brewin, J ^a   Lugthart, G ^a   Albon, S J ^a   Pule, M ^b   Amrolia, P J ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Calcineurin inhibitors resistance; Cytotoxic T lymphocytes; Epstein Barr virus; IFN selection; Posttransplant lymphoma; Solid organ transplant

Indexed keywords

CALCINEURIN INHIBITOR; CD8 ANTIGEN; GAMMA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS SPECIFIC CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL;

CALCINEURIN INHIBITORS RESISTANCE; CYTOTOXIC T LYMPHOCYTES; EPSTEIN-BARR VIRUS; IFN-Γ SELECTION; POSTTRANSPLANT LYMPHOMA; SOLID ORGAN TRANSPLANT;

ANTIGENS; CALCINEURIN; CELL PROLIFERATION; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOMA; MUTATION; ORGAN TRANSPLANTATION; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; RETROVIRIDAE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS;

EID: 84888368554     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12475     Document Type: Article

References (31)

1. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-168.
2. Bollard CM, Rooney CM, Heslop HE., T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9: 510-519.
3. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-814.
4. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.
5. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96: 10391-10396.
6. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415-1422.
7. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
8. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
9. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001; 72: 1078-1086.
10. Zhan X, Brown B, Slobod KS, Hurwitz JL., Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine. Transplantation 2003; 76: 739-740.
11. Brewin J, Mancao C, Straathof K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009; 114: 4792-4803.
12. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
13. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99: 2592-2598.
14. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565-3572.
15. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
16. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115: 2960-2970.
17. Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31: 39-48.
18. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK., High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
19. Hislop AD, Taylor GS, Sauce D, Rickinson AB., Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587-617.
20. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006; 82: 1093-1100.
21. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
22. Plosker GL, Foster RH., Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-389.
23. Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012; 20: 1622-1632.
24. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367.
25. Qasim W, Gilmour K, Zhan H, et al. Interferon-gamma capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol 2013; 161: 449-452.
26. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
27. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33: 305-315.
28. Finn L, Reyes J, Bueno J, Yunis E., Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22: 299-309.
29. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007; 86: 599-607.
30. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S., CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274.
31. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 2006; 367: 233-239.